Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lenalidomide

lenalidomide

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of lenalidomide

217 trials tracked of lenalidomide: 29 in phase 3 or 4 and 14 with published results. The most-cited published study has 1325 citations.

217Trials tracked
29Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 2 Phase 3 27 Phase 2 173 Phase 1 12 Other / NA 3
  1. Phase 3 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Completed · 1,325 cited
  2. Phase 3 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) Completed · 422 cited
  3. Phase 3 Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma Completed · 364 cited
  4. Phase 3 Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma Completed · 270 cited
  5. Phase 3 Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Completed · 260 cited
  6. Phase 3 A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Completed · 130 cited
Show 44 more trials
  1. Phase 3 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Completed · 114 cited
  2. Phase 3 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma Completed · 99 cited
  3. Phase 3 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma Completed · 47 cited
  4. Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma Completed · 45 cited
  5. Phase 3 A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy Completed · 35 cited
  6. Phase 3 Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) Completed · 28 cited
  7. Phase 3 A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Completed · 11 cited
  8. Phase 4 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Completed · 2 cited
  9. Phase 4 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed
  10. Phase 3 A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma Completed
  11. Phase 3 Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) Completed
  12. Phase 3 Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Completed
  13. Phase 3 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. Completed
  14. Phase 3 Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Completed
  15. Phase 3 Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer Completed
  16. Phase 3 Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma Completed
  17. Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed
  18. Phase 3 A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Completed
  19. Phase 3 A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Completed
  20. Phase 3 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Completed
  21. Phase 3 A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q Completed
  22. Phase 3 S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma Completed
  23. Phase 3 A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma Completed
  24. Phase 2 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma Completed
  25. Phase 2 Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
  26. Phase 2 Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma Completed
  27. Phase 2 Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma Completed
  28. Phase 2 Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) Completed
  29. Phase 2 Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia Completed
  30. Phase 2 Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia Completed
  31. Phase 2 Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD Completed
  32. Phase 2 Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) Completed
  33. Phase 2 Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma Completed
  34. Phase 2 Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL Completed
  35. Phase 2 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies Completed
  36. Phase 2 Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant Completed
  37. Phase 2 A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) Completed
  38. Phase 2 Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma Completed
  39. Phase 2 Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma Completed
  40. Phase 2 Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis Completed
  41. Phase 2 A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Completed
  42. Phase 2 Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease Completed
  43. Phase 2 Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma Completed
  44. Phase 2 Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma Completed

Showing the 50 most-cited and recently-updated of 217 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Indefinite-duration lenalidomide maintenance shows no significant difference in overall survival compared to fixed-duration
Oncology RCT
Indefinite-duration lenalidomide maintenance shows no significant difference in overall survival compared to fixed-duration Trial compares continuous versus fixed duration lenalidomide for myeloma
This Phase 3 randomized trial of 516 patients with standard-risk newly diagnosed multiple myeloma found that indefinite-duration lenalidomid…
A large trial found that continuing lenalidomide treatment indefinitely did not improve overall survival compared to a fixed two-year plan.
Jul 18, 2026
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma
Oncology RCT
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma Trial shows lenalidomide and rituximab for advanced follicular lymphoma
This Phase 3 randomized controlled trial of 1030 patients with previously untreated advanced follicular lymphoma found that the combination …
A large trial shows that a combination of two drugs can serve as an effective alternative to chemotherapy for patients with advanced follicu…
Blood Jun 20, 2026
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Oncology RCT
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Jun 20, 2026
Luspatercept and ESA-based regimens show higher rates of erythroid haematological improvement in lower-risk MDS
Oncology Meta-analysis
Luspatercept and ESA-based regimens show higher rates of erythroid haematological improvement in lower-risk MDS Different Medications Show Different Benefits for Myelodysplastic Syndromes
This systematic review and network meta-analysis of 20 trials involving 2,877 participants evaluated pharmacological treatments for lower-ri…
New research shows different medications offer varying benefits for patients with lower-risk myelodysplastic syndromes based on specific hea…
Frontiers Jun 17, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
Oncology FDA Approval
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
FDA May 2, 2026
Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma
Drug Pipeline RCT
Belantamab mafodotin plus lenalidomide and dexamethasone shows high response in unfit multiple myeloma Early trial shows promising results for a new drug combination in frail multiple myeloma patients
A Phase 1/2 randomized controlled trial in 42 RP2D patients with unfit, transplant-ineligible newly diagnosed multiple myeloma found an over…
A new drug combination helped 97.6% of frail multiple myeloma patients respond to treatment while keeping eye side effects manageable.
Blood Apr 17, 2026
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
Oncology Meta-analysis
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
Apr 16, 2026
Zanubrutinib-combined therapy in heavily treated non-GCB DLBCL: retrospective two-center cohort of 27 patients
Psychiatry Cohort
Zanubrutinib-combined therapy in heavily treated non-GCB DLBCL: retrospective two-center cohort of 27 patients New hope for tough lymphoma cases
A retrospective two-center cohort of 27 heavily treated patients with relapsed/refractory non-GCB DLBCL evaluated zanubrutinib-combined ther…
Combining zanubrutinib with other treatments helped 74% of patients with tough, hard-to-treat lymphoma respond after standard options failed…
Frontiers Apr 15, 2026
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients
Oncology Phase II
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…
Apr 12, 2026
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Allergy & Immunology Sys. Review
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Cochrane Apr 10, 2026
Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma
Oncology RCT
Carfilzomib-lenalidomide-dexamethasone improves progression-free survival versus lenalidomide after transplant in multiple myeloma Adding carfilzomib to lenalidomide improved survival in multiple myeloma patients after stem cell transplant
In a phase 3 trial of 180 patients with newly diagnosed multiple myeloma after autologous HSCT, carfilzomib-lenalidomide-dexamethasone maint…
Adding carfilzomib to lenalidomide after stem cell transplant boosted four-year survival to 67.5% compared to 38.0% for patients on lenalido…
Apr 9, 2026

All lenalidomide Articles